This content is machine translated Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer? Treat-to-Target – Consensus Recommendations for GC Tapering and the Use of DMARDs In addition to the EULAR (European Alliance of Associations for Rheumatology)/ACR (American College of Rheumatology) classification criteria, there are other validated tools that facilitate the early detection of SLE, such...…
View Post 6 min This content is machine translated C3 glomerulopathy—can its progression be halted? Iptacopan and Pegcetacoplan Open Up New Horizons To diagnose C3 glomerulopathy (C3G) and distinguish it from other membranoproliferative glomerulopathies, a kidney biopsy is required in addition to measuring the concentration of the complement protein C3 in the...…
View Post 6 min This content is machine translated CKD: Cardiorenal Benefits of nsMRA and GLP-1RA FIND-CKD and FLOW: Benefits Across Heterogeneous Patient Populations Finerenon significantly slowed the decline in kidney function in non-diabetic adults with chronic kidney disease (CKD) and also reduced the risk of cardiovascular complications —according to recently published data from...…
View Post 8 min This content is machine translated IgA Nephropathy: The Evolving Landscape of Treatment What are the most important game-changers? IgA nephropathy, also known as “Berger’s disease,” is the most common form of glomerulonephritis worldwide. It is an immune-mediated kidney disease diagnosed based on urine test results and a kidney...…
View Post 7 min This content is machine translated Lupus Nephritis – Countering the Attack on the Immune System Innovative adjunctive therapies promote renal remission Early diagnosis and treatment of lupus nephritis can be crucial for preserving kidney function. Among the adjunctive immunomodulatory therapies, two B-cell-targeted antibodies with different mechanisms of action—belimumab and obinutuzumab—are now...…
View Post 10 min This content is machine translated Switzerland's First PTH Replacement Therapy Palopegteriparatide for Chronic Hypoparathyroidism Chronic hypoparathyroidism is one of the few endocrine disorders for which no causal hormone replacement therapy has been available for decades. Treatment focused not on the underlying hormone deficiency, but...…
View Post 4 min This content is machine translated CKD and High Blood Pressure Keeping an Eye on Bidirectional Interactions Both hypertension and chronic kidney disease (CKD) are asymptomatic for long periods of time but pose serious health risks, underscoring the importance of timely screening in primary care. In this...…
View Post 18 min This content is machine translated From an antidiabetic drug to a distinct class of cardiorenal therapies The Incretin Revolution in Cardiology Within a decade, incretin mimetics have evolved from blood-sugar-lowering diabetes medications into one of the most dynamic classes of drugs in cardiovascular medicine. GLP-1 receptor agonists (GLP-1-RA) have been shown...…
View Post 8 min This content is machine translated Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases Pooled Expertise for Targeted Evaluation and Treatment According to the International Forum for the Study of Itch (IFSI), chronic pruritus can be classified into three categories. The etiological classification of pruritus on primarily non-lesional (IFSI II) skin...…
View Post 12 min This content is machine translated Why the Finerenon Boom Is Giving Hyperkalemia Treatment New Relevance Potassium binders as enablers of RAASi optimization Renin-angiotensin-aldosterone system (RAAS) inhibitors—including mineralocorticoid receptor antagonists (MRAs)—are among the most effective tools in cardiorenal medicine. However, their benefits are often undermined in everyday clinical practice because fear of hyperkalemia...…
View Post 5 min This content is machine translated CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes Approximately 30–40% of patients with type 2 diabetes develop chronic kidney disease (CKD) over time. In “landmark” studies such as CREDENCE, DAPA-CKD, EMPA-KIDNEY, and several others, SGLT-2 (sodium-glucose-linked transporter 2)...…
